Exact Sciences Corporation (EXAS)

Market Cap	10.68B
Revenue (ttm)	2.50B
Net Income (ttm)	-204.15M
Shares Out	181.53M
EPS (ttm)	-1.13
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,018,847
Open	59.02
Previous Close	58.79
Day's Range	58.45 - 60.31
52-Week Range	56.05 - 100.77
Beta	1.23
Analysts	Strong Buy
Price Target	91.14 (+54.87%)
Earnings Date	May 8, 2024

About EXAS

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Co...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1995
• Employees: 6,600
• Stock Exchange: NASDAQ
• Ticker Symbol: EXAS

Financial Performance

In 2023, Exact Sciences's revenue was $2.50 billion, an increase of 19.93% compared to the previous year's $2.08 billion. Losses were -$204.15 million, -67.26% less than in 2022.

Analyst Forecast

According to 15 analysts, the average rating for EXAS stock is "Strong Buy." The 12-month stock price forecast is $91.14, which is an increase of 54.87% from the latest price.

Price Target

$91.14

(54.87% upside)

Analyst Consensus: Strong Buy